Bernard Vanhove Ph.d

Bernard Vanhove has a strong background in research and development, with experience working in various leadership roles in the biopharmaceutical industry. Bernard has served as Chief Development Officer at Egle Therapeutics, Chief Operating Officer at XENOTHERA and OSE Immunotherapeutics, and Chief Executive Officer at Effimune. With a Ph.D. in Immunology from the University of Louvain, Bernard has also held research positions at CNRS and Inserm.